Research Spotlight

Tesamorelin: Research Overview

PūrTONIX Analytical TeamMarch 4, 20253 min read

Research Use Only — Regulatory Notice

All information contained in this article is derived exclusively from publicly available scientific literature, peer-reviewed academic publications, and publicly accessible research databases. This content is provided strictly for educational and informational purposes in the context of laboratory research.

PūrTONIX does not make any medical, therapeutic, or clinical claims. None of the compounds discussed have been approved by the U.S. Food and Drug Administration (FDA) for human use, diagnosis, treatment, or prevention of any disease or condition, except where explicitly noted for approved pharmaceutical forms.

This article does not constitute medical advice. These compounds are sold by PūrTONIX strictly as laboratory research reagents for in vitro use only. They are not intended for human or veterinary administration, dietary supplementation, or any therapeutic application.

All citations reference publicly available research. PūrTONIX makes no representations regarding the replication, accuracy, or applicability of any referenced study.

Compound Overview

Full name: Trans-3-hexenoyl-L-tyrosyl-L-alanyl-L-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-glycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminyl-L-glycyl-L-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-glutamyl-L-arginyl-L-glycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl-L-leucinamide
Molecular formula: C221H366N72O67S
Molecular weight: 5135.79 g/mol
Sequence / class: 44-residue modified human GHRH(1-44) analog with N-terminal trans-3-hexenoic acid acylation
Receptor targets: Growth hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor coupled to Gαs and downstream cAMP signaling
Research classification: GHRH receptor analog research peptide. Note: the approved pharmaceutical form is FDA-approved for specified clinical indications; the research-grade lyophilized reagent is supplied strictly for in vitro analytical use
PubChem CID: 16139605

Tesamorelin is a 44-residue analog of human growth hormone-releasing hormone (GHRH) modified at the N-terminus by acylation with trans-3-hexenoic acid. The full sequence reproduces residues 1-44 of human GHRH with the N-terminal modification that confers enhanced stability against dipeptidyl-peptidase-4 cleavage in published in vitro biochemistry studies. The molecular formula is C221H366N72O67S and the C-terminus carries a primary amide.

Published literature classifies tesamorelin as a GHRH receptor analog research compound. The molecule engages the GHRH receptor (GHRHR), a class B G-protein-coupled receptor coupled to Gαs with downstream cAMP accumulation, PKA activation, and characterized pituitary cellular signaling biochemistry in published in vitro reporter systems.

Research published in the peer-reviewed literature has used tesamorelin as an analytical reference compound in in vitro studies of GHRH receptor pharmacology. The extended functional half-life relative to native GHRH allows time-resolved signaling readouts to resolve cleanly across multi-hour cellular assay timecourses, which has made the analog a useful benchmark in comparative GHRH receptor research.

The research-grade lyophilized form is supplied strictly for in vitro analytical use. While an approved pharmaceutical formulation of the parent molecule carries FDA approval for a specified clinical indication, the research reagent supplied here is not formulated, sterilized, or characterized for human or veterinary administration and is sold solely as a laboratory analytical input.

Molecular Structure

Tesamorelin

C221H366N72O67S

Molecular weight 5135.79 g/mol

Structure reference: Public domain chemical databases (PubChem CID 16139605).

In Vitro Research Applications

The following applications reflect published in vitro and preclinical research only. None of these applications constitute approved medical use.

Published in vitro applications of tesamorelin include its use as a reference agonist in GHRHR reporter cell lines, primary pituitary cell preparations described in published research, and cAMP-accumulation assays that read out the proximal Gαs signaling event. Investigators have used the peptide to characterize EC50 values for GHRHR activation under controlled cellular assay conditions.

Receptor-binding studies indicate that tesamorelin produces sustained pathway activation across multi-hour in vitro timecourses, making it a useful comparator for time-resolved studies of GHRHR signaling kinetics. Published research has used the peptide to study receptor desensitization, internalization biochemistry, and the kinetics of intracellular cAMP responses in cellular reporter systems.

Comparative in vitro panels that include both tesamorelin and other GHRH-derived research peptides allow investigators to characterize how N-terminal modifications alter receptor engagement biochemistry under matched analytical conditions.

Published Research Highlights

[1]A study published in Journal of Clinical Endocrinology & Metabolism (2007) examined the analytical characterization of GHRH receptor analogs in publicly available reference pharmacology research.
[2]A study published in Peptides (2010) investigated GHRH receptor signaling kinetics using modified 44-residue analogs in cellular reporter systems.
[3]A study published in Endocrine Reviews (2003) reviewed publicly available literature on GHRH biochemistry and synthetic analog research reagents.

The above represents a non-exhaustive summary of publicly available research. PūrTONIX does not endorse, validate, or make claims based on any referenced study.

Analytical Considerations for Laboratory Use

Published chemical property data indicate that tesamorelin is soluble in mildly acidic to neutral aqueous buffer. The lyophilized peptide is stored at -20°C under inert atmosphere with attention to the single methionine residue, which is susceptible to oxidation under uncontrolled storage. Reconstituted stocks are held in single-use aliquots for reproducible in vitro signaling measurements.

Reconstitution in bacteriostatic water or in assay-matched buffer is standard for GHRHR pharmacology assays. Analytical characterization commonly includes reverse-phase HPLC purity analysis, electrospray mass spectrometry confirming the 44-residue sequence with intact N-terminal acylation, and residual solvent screening per ICH Q3C.

Handling recommendations are based on published chemical property data and are intended for qualified laboratory personnel only.

Research-Grade Sourcing Standards

Class B GPCR reporter assays at sub-nanomolar agonist concentrations depend on high chromatographic purity. Documented mass-spectral identity confirming the N-terminal trans-3-hexenoic acid modification is typically reported in analytical documentation for this class of compound.

Browse Product Documentation →